Junhasavasdikul Saowapak, Panburana Panyu, Bumrungphuet Sommart, Dulyaphat Wirada
Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Faculty of Medicine, Mahidol University, Ramathibodi Hospital, Bangkok, Thailand.
Int J Womens Health. 2022 Oct 17;14:1465-1476. doi: 10.2147/IJWH.S373087. eCollection 2022.
Gestational diabetes mellitus (GDM) has an impact on fetal adrenal gland size and volume, which are greater in the GDM population. This study used 2D and 3D ultrasound scanning to determine the correlation of fetal adrenal gland size and volume with fructosamine levels, HbA1c levels, estimated fetal weight (EFW), and neonatal birth weight in GDM patients.
This study included eighty singleton pregnant women diagnosed with GDM between 24-28 weeks of gestation. During weeks 32-34 of gestation, the length, width, and depth of the fetal zone and total adrenal gland were measured using transabdominal 2D ultrasound. Virtual organ computer-aided analysis (VOCAL) software was used to evaluate fetal zone and total adrenal gland volume in 3D ultrasound. All the participants were followed until delivery. Pearson's correlation analysis was conducted to examine the correlation between fetal adrenal gland ultrasound measurements and the factors of interest.
The study consisted of sixty-six (82.5%) pregnant women with diet-controlled GDM (GDMA1) and fourteen (17.5%) pregnant women with insulin-managed GDM (GDMA2). There was no difference in fetal adrenal gland measurements between the diet-controlled (GDMA1) and the insulin-managed (GDMA2) groups. All the participants had achieved optimal glucose levels at the time of ultrasound acquisition. The total adrenal gland length and fetal zone volume had statistically significant positive correlations with EFW (r = 0.69, p = 0.02 and r = 0.84, p = 0.01, respectively). After adjusting for EFW, only the fetal zone volume was significantly correlated with fructosamine levels (adjusted-OR = 2.4, 95% CI: 1.5, 3.9, p = 0.01) and HbA1c levels (adjusted-OR = 2.5, 95% CI: 1.6, 4.3, p = 0.01).
The fetal zone volume is correlated with EFW, fructosamine levels, and HbA1c levels. This non-invasive technique may be beneficial as an indirect marker for glycemic monitoring in GDM.
妊娠期糖尿病(GDM)会影响胎儿肾上腺的大小和体积,GDM人群中的胎儿肾上腺更大。本研究采用二维和三维超声扫描来确定GDM患者胎儿肾上腺大小和体积与果糖胺水平、糖化血红蛋白(HbA1c)水平、估计胎儿体重(EFW)及新生儿出生体重之间的相关性。
本研究纳入了80名单胎孕妇,她们在妊娠24至28周时被诊断为GDM。在妊娠32至34周期间,采用经腹二维超声测量胎儿肾上腺区及整个肾上腺的长度、宽度和深度。使用虚拟器官计算机辅助分析(VOCAL)软件在三维超声下评估胎儿肾上腺区及整个肾上腺的体积。所有参与者均随访至分娩。采用Pearson相关分析来检验胎儿肾上腺超声测量值与相关因素之间的相关性。
该研究包括66名(82.5%)饮食控制的GDM孕妇(GDMA1)和14名(17.5%)胰岛素治疗的GDM孕妇(GDMA2)。饮食控制组(GDMA1)和胰岛素治疗组(GDMA2)之间胎儿肾上腺测量值无差异。所有参与者在超声检查时血糖水平均达到最佳状态。整个肾上腺长度和胎儿肾上腺区体积与EFW呈显著正相关(r分别为0.69,p = 0.02和r = 0.84,p = 0.01)。在对EFW进行校正后,仅胎儿肾上腺区体积与果糖胺水平(校正比值比=2.4,95%可信区间:1.5,3.9,p = 0.01)和HbA1c水平(校正比值比=2.5,95%可信区间:1.6,4.3,p = 0.01)显著相关。
胎儿肾上腺区体积与EFW、果糖胺水平和HbA1c水平相关。这种非侵入性技术作为GDM血糖监测的间接指标可能有益。